EVFM (Evofem Biosciences) EBITDA Margin %: -495.88% (As of Mar. 2026)


What is Evofem Biosciences EBITDA Margin %?

Evofem Biosciences EVFM -0.06% EBITDA Margin % is -495.88% as of Mar. 2026. The stock has 5 warning signs investors should review. Among 945 Biotechnology companies, Evofem Biosciences ranks better than 61.16% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Evofem Biosciences's EBITDA for the three months ended in Mar. 2026 was $-4.46 Mil. Evofem Biosciences's Revenue for the three months ended in Mar. 2026 was $0.90 Mil. Therefore, Evofem Biosciences's EBITDA margin for the quarter that ended in Mar. 2026 was -495.88%.

Evofem Biosciences  (OTCPK:EVFM) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Evofem Biosciences EBITDA Margin % Related Terms

Evofem Biosciences EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Evofem Biosciences's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evofem Biosciences EBITDA Margin % Chart

Evofem Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,010.89 -487.49 -88.19 -35.74 10.23

Evofem Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 70.18 -23.13 -17.45 36.11 -495.88

EVFM vs PTIX, ATXI, AGTX: EBITDA Margin % Comparison

For the Biotechnology subindustry, Evofem Biosciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evofem Biosciences EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evofem Biosciences's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Evofem Biosciences's EBITDA Margin % falls into.


Evofem Biosciences EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Evofem Biosciences's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=2.065/20.183
=10.23 %

Evofem Biosciences's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-4.458/0.899
=-495.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -495.88% mean?
Evofem Biosciences (EVFM) has a EBITDA Margin % of -495.88% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Evofem Biosciences and its competitors. According to the industry distribution chart, Evofem Biosciences ranks #367 out of 945 companies in the Biotechnology industry, placing it in the top 38.8%.
Is Evofem Biosciences' EBITDA Margin % too high?
Evofem Biosciences' current EBITDA Margin % is -495.88%. Based on the distribution chart, Evofem Biosciences ranks #367 out of 945 companies in the Biotechnology industry, which is above the industry midpoint.
How does Evofem Biosciences' EBITDA Margin % compare to PTIX and ATXI?
According to the Biotechnology industry distribution chart, Evofem Biosciences ranks #367 out of 945 companies for EBITDA Margin %. This puts Evofem Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Evofem Biosciences and its competitors. Evofem Biosciences's current EBITDA Margin % is -495.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evofem Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Evofem Biosciences (EVFM) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 12.8% below its estimated fair value. The current EBITDA Margin % is -495.88%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Evofem Biosciences (EVFM), the current EBITDA Margin % is -495.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evofem Biosciences Business Description

Address 7770 Regents Road, Suite 113-618, San Diego, CA, USA, 92122
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.